|Study Description:||The goal of this clinical research study is to learn if BRAFi |
(GSK2118436--dabrafenib) or the combination of dabrafenib and MEKi
(GSK1120212--trametinib) can help to control BRAF-mutated thyroid cancer. The
safety of these drugs will also be studied.
Dabrafenib (BRAFi) is designed to block the mutated BRAF protein. By blocking
the protein, the drug may slow the growth of or kill cancer cells that have the
Trametinib (MEKi) is designed to block certain proteins that cause cancer cells
to grow and multiply. This may cause the cancer cells to die.